BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Biotechnology

BenevolentAI

Joerg Moeller

Judit Molnar M.D.

James Malone

Anna Fullerton-Batten

Will Scrimshaw

Ivan Griffin

Anne Phelan

Leadership Team

Engineering Team

Data Science Team

Drug Discovery and Pharmacology

Teams at BenevolentAI

Leadership Team

Engineering Team

Data Science Team

Drug Discovery and Pharmacology